Suivre
Abonner Antisoma plc

Antisoma plc

Filtre
  • 04.11.2003 – 12:22

    Antisoma promotes Nick Adams to Director of Business Development

    London, UK (ots) - Antisoma, (LSE: ASM) the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the promotion of Mr Nicholas Adams to Director of Business Development. Nick will lead Antisoma's business development team, for which a key focus remains the acquisition of new products to add to Antisoma's pipeline. He has also been appointed to Antisoma's Executive ...

  • 10.09.2003 – 08:39

    Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology

    London, UK (ots) - Antisoma plc, (LSE: ASM; Nasdaq Europe: ASOM) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has in-licensed a programme of telomerase inhibitors from Cancer Research Technology Ltd, the technology transfer arm of the charity Cancer Research UK. This programme was developed by Professor Stephen ...

  • 09.09.2003 – 08:38

    Antisoma Acquires Cytogen's Royalty Rights To R1549

    London, UK and Princeton, New Jersey USA (ots) - Antisoma plc (LSE: ASM; Nasdaq Europe: ASOM), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation (Nasdaq: CYTO), a United States-based, product-driven, oncology-focused biopharmaceutical company, today announced that Antisoma has acquired certain royalty rights to Antisoma's lead product, R1549 (formerly Pemtumomab), from Cytogen. In connection ...

  • 22.08.2003 – 08:17

    Results Presented From As1403 Phase I Biodistribution Study

    London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...